Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Neurocrine Biosciences

Tracked across 3 events · 59 articles · First seen Apr 01, 2026 · Last active May 28, 2026

Sentiment
52
Attention
6
Events
3
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Business
Impact: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio in endocrinology and rare diseases with the addition of VYKAT XR. This acquisition is expected to accelerate revenue growth and diversify its product offerings.
Apr 06, 2026 · 6 articles
6 70
Business
Impact: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio into metabolic disorders with the addition of VYKAT XR. This deal is seen as a strategic entry into the metabolic disease market.
Apr 06, 2026 · 6 articles
2 10
Business
Impact: Neurocrine Biosciences, Inc. is the proposed acquirer of MiNK Therapeutics.
Apr 01, 2026 · 47 articles
MiNK Therapeutics Neurocrine Biosciences
MiNK Therapeutics Neurocrine Biosciences
ERGEN INTELLIGENCE
Track Neurocrine Biosciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.